Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.04Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed a predominantly positive commercial and financial momentum: record revenues (+16% YoY), strong product and EMEA growth, rapidly expanding IFC demand and continued positive adjusted EBITDA and cash runway. Key strategic milestones were achieved including CE Mark and commercial launch of INT200, completion of U.S. RedeS enrollment, and a major group purchasing agreement with BCA that could materially expand U.S. penetration. Offsetting these positives are margin compression driven by higher IFC production costs, import tariffs and inflation, an expected taper in BARDA-reimbursed R&D revenue as the contract expires, and ongoing regulatory/timing uncertainties for RBC approvals. Overall, the positives (strong revenue and demand growth, improving profitability metrics, strategic partnerships and product launches) outweigh the challenges, while management continues to highlight areas of uncertainty that could affect near-term margins and timing.Company Guidance
Record Annual Revenue
Total revenues for 2025 were $233.8 million (record), up 16% year-over-year versus 2024.
Product Revenue Beat and Growth
Record product revenue rose 14% for both the quarter and full year, exceeding prior guidance of $202M–$204M.
Strong EMEA Performance
EMEA product revenue (ex-FX) increased 25% in Q4 and 14% for the full year; growth driven by platelet and plasma kit sales and early INT200 rollout.
IFC Demand and Revenue Acceleration
IFC Q4 product revenue was $4.2M vs. $3.0M in Q4 2024 (~40% increase). Full-year IFC product sales were $16.7M vs. $9.2M in 2024 (~80% growth). Underlying IFC volume increased ~110% year-over-year.
Shift to Kit-Based IFC Model
In Q4, ~70% of IFC sales were kits (up from ~50% prior year); company expects nearly all IFC sales to be kit-based by year-end, supporting scalable production by blood centers.
INT200 Regulatory and Commercial Progress
Received CE Mark and commercially launched INT200 in Europe with positive customer feedback; on track to submit U.S. PMA for INT200 in mid-2026.
Red Blood Cell Program Milestones
TÜV review of RBC dossier completed and file being transferred to ANSM for consultation; U.S. RedeS Phase III enrollment complete with topline results expected late 2026.
Strategic BCA Agreement
Group purchasing agreement with Blood Centers of America effective Jan 1; BCA members account for ~50% of U.S. blood supply and estimate ~30% current INTERCEPT penetration within BCA, enabling broader adoption and streamlined contracting.
Profitability and Cash Position
Q4 adjusted EBITDA of $3.4M (seventh consecutive positive quarter); full-year adjusted EBITDA $9.5M (second consecutive positive year). GAAP net loss narrowed to $15.6M for full year (down 25% YoY). Cash and short-term investments totaled ~$83M at year-end.
2026 Revenue Guidance and IFC Outlook
Reaffirming 2026 product revenue guidance of $224M–$228M (+9% to +11% YoY). Included IFC revenue guidance $20M–$22M (+~20% to +30% YoY). Management expects continued positive adjusted EBITDA in 2026.
Commercial Momentum in Key Markets
Notable international traction including Germany (INITIATE Phase IV study started) — Germany platelet opportunity estimated at ~$30M annual; growth also noted in Middle East markets such as Saudi Arabia, Kuwait and Qatar.
CERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 02, 2026 | $2.53 | $2.13 | -15.81% |
Nov 06, 2025 | $1.41 | $1.71 | +21.28% |
Aug 05, 2025 | $1.28 | $1.29 | +0.78% |
May 01, 2025 | $1.30 | $1.35 | +3.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cerus Corp (CERS) report earnings?
Cerus Corp (CERS) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Cerus Corp (CERS) earnings time?
Cerus Corp (CERS) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CERS EPS forecast?
CERS EPS forecast for the fiscal quarter 2026 (Q1) is -0.05.